Merck & Co., Inc. (NYSE: MRK) announced in a filing on October 13, 2026, that Paul J. Diaz has been elected to the company’s Board of Directors, effective November 1, 2026.
The filing indicates that Mr. Diaz will serve as a non-employee director and will be appointed to both the Audit Committee and the Research Committee of the Board.
According to the company’s press release, Mr. Diaz is a managing partner at Cressey & Company, a private investment firm focused on healthcare. His professional background includes serving as the president and chief executive officer of Myriad Genetics, Inc., and previously leading Kindred Healthcare, a Fortune 500 healthcare services company.
Mr. Diaz will stand for election by the company’s shareholders in May 2027. With his appointment, the Merck Board will consist of 14 members.
Merck & Co., Inc. is headquartered in Rahway, New Jersey, and is known as MSD outside of the United States and Canada.
